Ulcerative Colitis

Immunology·MeSH: Colitis, Ulcerative

Prevalence

263.0 / 100K

Incidence

9.0 / 100K/yr

76 drugs in development·42 companies·58 clinical trials

Drug Pipeline by Phase

Approved(16)

Drug	Company
abrilada	PFIZER INC (PFE)
Hadlima (SB5)	Organon & Co. (OGN)
imuldosa	Acorda Therapeutics, Inc. (ACOR)
inFoods® (IBS)	BIOMERICA INC (BMRA)
mesalamine	Mylan II B.V. (MYL)
mesalamine	Amneal Pharmaceuticals, Inc. (AMRX)
Omvoh	ELI LILLY & Co (LLY)
OmvohTM	ELI LILLY & Co (LLY)
Renflexis (SB2)	Organon & Co. (OGN)
Tremfya	Royalty Pharma plc (RPRX)
triamcinolone acetonide	Teva Pharmaceutical Industries Limited (TEVA)
Uceris authorized generic	Bausch Health Companies Inc. (BHC)
velsipity	PFIZER INC (PFE)
wezlana	AMGEN INC (AMGN)
xeljanz xr	PFIZER INC (PFE)
yesintek	Bone Biologics Corp (BBLG)

Phase 3(15)

Drug	Company
abx464	Abivax SA (ABVX)
ABX464	Abivax SA (ABVX)
duvakitug	Sanofi (SNY)
duvakitug	Sanofi (SNYNF)
IV Tulisokibart	Merck & Co., Inc. (MRK)
Mirikizumab IV	ELI LILLY & Co (LLY)
Mirikizumab SC	ELI LILLY & Co (LLY)
ozanimod	BRISTOL MYERS SQUIBB CO (BMY)
ozanimod	CELGENE CORP /DE/ (CELG)
SC Tulisokibart	Merck & Co., Inc. (MRK)
tak-279	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
tak-279	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
vedolizumab	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
Vedolizumab	AbbVie Inc. (ABBV)
vedolizumab sc	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)

Phase 2(23)

Drug	Company
bertilimumab	IMMUNE PHARMACEUTICALS INC (IMNP)
Eltrekibart	ELI LILLY & Co (LLY)
emvistegrast	GILEAD SCIENCES, INC. (GILD)
etrasimod	PFIZER INC (PFE)
fxr314	VivoSim Labs, INC. (VIVS)
LY4268989	ELI LILLY & Co (LLY)
met642	Metacrine, Inc. (MTCR)
Mirikizumab	ELI LILLY & Co (LLY)
morf-057	Morphic Holding, Inc. (MORF)
nx-13	Landos Biopharma, Inc. (LABP)
nx-13	AbbVie Inc. (ABBV)
od-07656	Odyssey Health, Inc. (ODYY)
pl8177	PALATIN TECHNOLOGIES INC (PTN)
Rosnilimab	ANAPTYSBIO, INC (ANAB)
sar442970	Sanofi (SNY)
SAR442970	Sanofi (SNY)
SER-287	Seres Therapeutics, Inc. (MCRB)
SPY001	Spyre Therapeutics, Inc. (SYRE)
SPY002	Spyre Therapeutics, Inc. (SYRE)
SPY003	Spyre Therapeutics, Inc. (SYRE)
tamuzimod	Ventyx Biosciences, Inc. (VTYX)
Tulisokibart	Merck & Co., Inc. (MRK)
vedolizumab	Odyssey Health, Inc. (ODYY)

Phase 1(4)

Drug	Company
bt-600	BIORA THERAPEUTICS, INC. (BIOR)
pali-2108	PALISADE BIO, INC. (PALI)
pt101	Pandion Therapeutics, Inc. (PAND)
SER-301	Seres Therapeutics, Inc. (MCRB)

Preclinical(5)

Drug	Company
bt-001	BIORA THERAPEUTICS, INC. (BIOR)
eq504	Equillium, Inc. (EQ)
kb295	Kaleido Biosciences, Inc. (KLDO)
ser-603	Seres Therapeutics, Inc. (MCRB)
zegocractin (oral, preclinical administration)	CalciMedica, Inc. (CALC)

Unknown(3)

Drug	Company
CLS-001	Comera Life Sciences Holdings, Inc. (CMRA)
InFoods® platform (other disease targets)	BIOMERICA INC (BMRA)
Non-Interventional Study	PFIZER INC (PFE)

BLA Filed(1)

Drug	Company
m923	MOMENTA PHARMACEUTICALS INC (MNTA)

Phase 1/Phase 2(1)

Drug	Company
XmAb942	Xencor Inc (XNCR)

Phase 4(8)

Drug	Company
Risankizumab	AbbVie Inc. (ABBV)
vedolizumab	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
vedolizumab	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
vedolizumab iv	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
vedolizumab iv	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
vedolizumab iv	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
vedolizumab sc	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
vedolizumab sc	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)

BioSniper tracks 76 drugs in development for Ulcerative Colitis across 42 companies.

There are 58 clinical trials targeting Ulcerative Colitis tracked by BioSniper.

The estimated prevalence of Ulcerative Colitis is approximately 263.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.